Portal Access secures $7M for chemotherapy port

The article discusses Portal Access, an oncology-focused medical device startup, that recently closed a $7 million Series A financing round. The funding was led primarily by U.S. physician investors, with additional support from a U.S.-based venture capital fund. The company’s flagship product is the Flexi-Port SLF-TANL, a subcutaneous port designed to simplify vascular access for oncology patients. The funds will be used for FDA approval and a 2026 U.S. market launch of the device, which is aimed at reducing treatment delays, procedural risks, and healthcare costs in oncology settings.

Highlights of the article:
1. Portal Access secures $7 million in Series A financing led by U.S. physician investors for their oncology-focused medical device startup.
2. The company’s Flexi-Port SLF-TANL aims to improve vascular access for oncology patients, with plans for FDA approval and a U.S. market launch in 2026.
3. The device is projected to enhance efficiency in oncology settings, minimize treatment delays, and reduce total healthcare costs.

In summary, Portal Access successfully raised significant funding for their innovative medical device designed to streamline vascular access for oncology patients. The company’s focus on improving patient outcomes and experiences while addressing healthcare costs is a promising development in the oncology space.

Editorial content by NewsSIP AI